A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5399
Abstract: Introduction: Brentuximab vedotin (BV) was approved by the US FDA for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in 2011 and for previously untreated advanced stage cHL in 2018. The immune checkpoint inhibitors (ICIs) nivolumab and… read more here.
Keywords: era; ici era; chemo era; chl ... See more keywords